Gyre Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $119.9M | $31.2M |
| FY2019 | — | $68.3M | $15.4M |
| FY2020 | — | $76.1M | $30.4M |
| FY2021 | — | $41.1M | $44.3M |
| FY2022 | — | $42.5M | $25.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $119.9M | $31.2M |
| FY2019 | — | $68.3M | $15.4M |
| FY2020 | — | $76.1M | $30.4M |
| FY2021 | — | $41.1M | $44.3M |
| FY2022 | — | $42.5M | $25.2M |